U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Prolonged G2 phase of cell cycle

MedGen UID:
871165
Concept ID:
C4025639
Cell or Molecular Dysfunction
HPO: HP:0003214

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVProlonged G2 phase of cell cycle

Conditions with this feature

Fanconi anemia complementation group D2
MedGen UID:
463627
Concept ID:
C3160738
Disease or Syndrome
Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.
Fanconi anemia complementation group E
MedGen UID:
463628
Concept ID:
C3160739
Disease or Syndrome
Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.
Fanconi anemia complementation group C
MedGen UID:
483324
Concept ID:
C3468041
Disease or Syndrome
Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.
Fanconi anemia complementation group A
MedGen UID:
483333
Concept ID:
C3469521
Disease or Syndrome
Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.

Professional guidelines

PubMed

Karatkevich D, Deng H, Gao Y, Flint E, Peng RW, Schmid RA, Dorn P, Marti TM
Int J Mol Sci 2022 Oct 8;23(19) doi: 10.3390/ijms231911949. PMID: 36233258Free PMC Article
Alberti C
Eur Rev Med Pharmacol Sci 2013 Jun;17(12):1658-64. PMID: 23832735
Komrokji RS, List AF
Hematol Oncol Clin North Am 2010 Apr;24(2):377-88. doi: 10.1016/j.hoc.2010.02.013. PMID: 20359632

Recent clinical studies

Etiology

Cevatemre B, Bulut I, Dedeoglu B, Isiklar A, Syed H, Bayram OY, Bagci-Onder T, Acilan C
Cell Death Dis 2024 Feb 12;15(2):132. doi: 10.1038/s41419-024-06422-1. PMID: 38346967Free PMC Article
Huang H, Zhao X, Shi X, Tan Q, Zhang R, Yue M, Ma R, Chen Q, Zhao S, Yang L
Endokrynol Pol 2022;73(2):346-352. doi: 10.5603/EP.a2022.0025. PMID: 35593683
Al-Ghorbani M, Thirusangu P, Gurupadaswamy HD, Vigneshwaran V, Mohammed YH, Prabhakar BT, Khanum SA
Bioorg Chem 2017 Apr;71:55-66. Epub 2017 Jan 18 doi: 10.1016/j.bioorg.2017.01.011. PMID: 28139247
Komrokji RS, List AF
Hematol Oncol Clin North Am 2010 Apr;24(2):377-88. doi: 10.1016/j.hoc.2010.02.013. PMID: 20359632
Alm K, Oredsson S
Essays Biochem 2009 Nov 4;46:63-76. doi: 10.1042/bse0460005. PMID: 20095970

Diagnosis

Cevatemre B, Bulut I, Dedeoglu B, Isiklar A, Syed H, Bayram OY, Bagci-Onder T, Acilan C
Cell Death Dis 2024 Feb 12;15(2):132. doi: 10.1038/s41419-024-06422-1. PMID: 38346967Free PMC Article
Boulos JC, Omer EA, Rigano D, Formisano C, Chatterjee M, Leich E, Klauck SM, Shan LT, Efferth T
Acta Pharmacol Sin 2023 Nov;44(11):2265-2281. Epub 2023 Jun 21 doi: 10.1038/s41401-023-01117-3. PMID: 37344563Free PMC Article
Sunada S, Saito H, Zhang D, Xu Z, Miki Y
Biochem Biophys Res Commun 2021 Apr 23;550:56-61. Epub 2021 Mar 5 doi: 10.1016/j.bbrc.2021.02.117. PMID: 33684621
Rieder CL, Cole RW
Cell Cycle 2002 May-Jun;1(3):169-75. PMID: 12429927
Dorr RT
Pharmacotherapy 1997 Sep-Oct;17(5 Pt 2):96S-104S. PMID: 9322876

Therapy

Cevatemre B, Bulut I, Dedeoglu B, Isiklar A, Syed H, Bayram OY, Bagci-Onder T, Acilan C
Cell Death Dis 2024 Feb 12;15(2):132. doi: 10.1038/s41419-024-06422-1. PMID: 38346967Free PMC Article
Lang F, Cornwell JA, Kaur K, Elmogazy O, Zhang W, Zhang M, Song H, Sun Z, Wu X, Aladjem MI, Aregger M, Cappell SD, Yang C
Neuro Oncol 2024 Jun 3;26(6):1083-1096. doi: 10.1093/neuonc/noad252. PMID: 38134889Free PMC Article
Boulos JC, Omer EA, Rigano D, Formisano C, Chatterjee M, Leich E, Klauck SM, Shan LT, Efferth T
Acta Pharmacol Sin 2023 Nov;44(11):2265-2281. Epub 2023 Jun 21 doi: 10.1038/s41401-023-01117-3. PMID: 37344563Free PMC Article
Karatkevich D, Deng H, Gao Y, Flint E, Peng RW, Schmid RA, Dorn P, Marti TM
Int J Mol Sci 2022 Oct 8;23(19) doi: 10.3390/ijms231911949. PMID: 36233258Free PMC Article
Liu W, Ma H, Liang R, Chen X, Li H, Lan T, Yang J, Liao J, Qin Z, Yang Y, Liu N, Li F
Mol Pharm 2022 Sep 5;19(9):3206-3216. Epub 2022 Aug 22 doi: 10.1021/acs.molpharmaceut.2c00349. PMID: 35993583

Prognosis

Gao S, Tan H, Gang J
J Ethnopharmacol 2024 Jul 15;329:118001. Epub 2024 Mar 11 doi: 10.1016/j.jep.2024.118001. PMID: 38467318
Hartfiel S, Häfner M, Perez RL, Rühle A, Trinh T, Debus J, Huber PE, Nicolay NH
Radiat Oncol 2019 Jul 8;14(1):119. doi: 10.1186/s13014-019-1326-9. PMID: 31286978Free PMC Article
Zhang HT, Yang J, Liang GH, Gao XJ, Sang Y, Gui T, Liang ZJ, Tam MS, Zha ZG
J Cell Biochem 2017 Dec;118(12):4575-4586. Epub 2017 Sep 7 doi: 10.1002/jcb.26122. PMID: 28485543
Komrokji RS, List AF
Hematol Oncol Clin North Am 2010 Apr;24(2):377-88. doi: 10.1016/j.hoc.2010.02.013. PMID: 20359632
Cho NH, Kim YT, Kim JW
Yonsei Med J 2002 Dec;43(6):722-8. doi: 10.3349/ymj.2002.43.6.722. PMID: 12497655

Clinical prediction guides

Cevatemre B, Bulut I, Dedeoglu B, Isiklar A, Syed H, Bayram OY, Bagci-Onder T, Acilan C
Cell Death Dis 2024 Feb 12;15(2):132. doi: 10.1038/s41419-024-06422-1. PMID: 38346967Free PMC Article
Ji J, Jing A, Ding Y, Ma X, Qian Q, Geng T, Cheng W, Zhang M, Sun Q, Ma S, Wang X, Yuan Q, Xu M, Qin J, Ma L, Yang J, He J, Du Q, Xia M, Xu Y, Chen Z, Zhu L, Liu W, Liu S, Liu B
Cell Death Dis 2024 Jan 11;15(1):33. doi: 10.1038/s41419-024-06421-2. PMID: 38212299Free PMC Article
Karatkevich D, Deng H, Gao Y, Flint E, Peng RW, Schmid RA, Dorn P, Marti TM
Int J Mol Sci 2022 Oct 8;23(19) doi: 10.3390/ijms231911949. PMID: 36233258Free PMC Article
Peischard S, Ho HT, Theiss C, Strutz-Seebohm N, Seebohm G
Cell Physiol Biochem 2019;53(1):121-140. doi: 10.33594/000000125. PMID: 31230428
Zhang HT, Yang J, Liang GH, Gao XJ, Sang Y, Gui T, Liang ZJ, Tam MS, Zha ZG
J Cell Biochem 2017 Dec;118(12):4575-4586. Epub 2017 Sep 7 doi: 10.1002/jcb.26122. PMID: 28485543

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...